

## *Supplementary Material*

### **1 Supplementary Data**

#### *Nuclear factor- $\kappa$ B (NF- $\kappa$ B) reporter gene activity assay*

NF- $\kappa$ B reporter gene activity was measured as previously reported[30]. HEK293T cells, in 96-well plates, were transfected with 10 ng per well of the following vectors: a pcDNA3.1+ mock vector, pcDNA3.1+ containing WT myc-A20, or pcDNA3.1+ containing myc-A20 variants. DNA transfection was carried out using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. The NF- $\kappa$ B luciferase reporter construct and a *Renilla* luciferase control were co-transfected into the cells. After transfection, cells were incubated for 24 hours, and then stimulated with 20 ng/mL tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) (R&D Systems, Inc., Minneapolis, MN) for 6 hours. Luciferase reporter activity was analyzed using the Dual-Luciferase Reporter Assay System (Promega, Madison, WI). The activity values for WT and each variant were normalized to that of the mock vector transfection, stimulated with 20 ng/mL TNF- $\alpha$ .

## 2 Supplementary Figures and Tables

Table S1: Details of the numbers of patients and samples from each disease group.

	Number of patients	Number of samples	Details
Healthy controls	11	11	
Pediatric controls	12	12	
AGS1	2	2	
AGS5	1	1	
AGS7	2	2	
SAVI	3	3	
COPA	2	2	
PRAAS	4	5	1 patient was evaluated twice.
SPENCDI	2	2	
SLE	2	2	
DLE	1	1	
DM	7	7	
CGD	2	3	1 patient was evaluated twice.
Early-onset Behcet's disease	1	1	
HA20	9	9	
IPH	3	5	2 patients were evaluated twice.
CAEBV	1	1	
HMB	1	3	1 patient was evaluated three times.
Kawasaki disease	1	1	
Takayasu arthritis	2	2	
CAPS	2	2	
FMF	2	4	2 patients were evaluated twice.
PAAND	1	1	
PFAPA	6	6	
Undiagnosed	37	52	Patients with a low IS were evaluated once. Some patients with a high IS were evaluated multiple times, details of which are described in Table 2.
Total	117	140	

Table S2: Genotypes and clinical phenotypes of patients with A 20 haploinsufficiency.

Patient	Gender	Age at IS analysis	Disease-onset age	IS	genotype	Initial diagnosis before genetic analysis	CRP at IS analysis (mg/L)	Symptoms at IS analysis	Treatment at IS analysis
1	F	37y	Infancy	40.3	c.986+1 G>T, p.Lys329Asn*1 hetero	SLE (Recurrent fever, lymphadenitis, arthritis)	N/D	None	PSL, Hydroxychloroquine
2	M	15y	4y	41.0	c.133C>T, p.Arg45* hetero	Crohn's disease	N/D	None	Colchicine, Mesalamin
3	F	6y	7m	51.7	c.1747G>T, p.Gly583* hetero	Recurrent fever with arthralgia and abdominal pain	7	None	No treatment
4	M	10y	1y1m	48.2	c.133C>T, p.Arg45* hetero	PFAPA-like recurrent fever → intestinal Behçet's disease	5	Stomatitis	Colchicine
5 <sup>a</sup>	F	5y	6m	46.2	c.2209delC, p.Gln737Serfs*79 hetero	FMF like autoinflammatory disease	<0.2	None	Etanercept
6 <sup>a</sup>	F	29y	5y	56.0	c.2209delC, p.Gln737Serfs*79 hetero	Crohn's disease, Hashimoto's disease	7.1	None	No treatment
7 <sup>a</sup>	F	68y	Early childhood	44.3	c.2209delC, p.Gln737Serfs*79 hetero	Recurrent stomatitis, Hashimoto's disease	N/D	None	No treatment
8	F	19y	11y	27.1	c.252delC, p.Trp85Glyfs*11 hetero	RF negative pJIA → intestinal BD	0.8	None	ADA, PSL, Celecoxib, Igaratimod
9	M	4y	1y	24.7	c.2088+5G>C, p.His636Glufs*55 hetero	sJIA → Psoriatic arthritis	11.3	Skin erythema, adrenal insufficiency	IFX, MTX, PSL, Naproxen, Colchicine

a: Patients 6 and 7 are the mother and grandmother of patient 5, respectively.

M: male, F: female, PSL: prednisolone, ADA: adalimumab, IFX: infliximab, MTX: methotrexate

Table S3: Clinical phenotypes of patients with idiopathic pulmonary hemorrhage.

Patient	Gender	Age at IS analysis	Disease-onset age	IS	Clinical manifestation at diagnosis				Extrapulmonary manifestations	Symptoms at IS analysis	Auto-antibodies	Hemosiderin-laden macrophages	Treatment	Genotype
					Anemia	Cough	Dyspnea	Hemoptysis						
1	F	15y	4y	93.7/48.6	+	+	+	+	None	None	ANA 1:320, Anti-ssDNA, Anti-dsDNA, Anti-SS-A	+(gastric aspirate)	PSL, AZA, ICS, CAM	No pathogenic mutations found in the NGS-based gene panel test
2	F	13y	4y	11.2/13.5	+	+	-	+	None	None	ANA 1:80	+(sputum)	PSL, ICS, CAM	Not analyzed
3	F	20y	2w	1.62	+	+	+	+	Arthralgia, morning stiffness, annular erythema	None	ACPA, RF	N/D	Iguratimod (for arthralgia)	No mutations in the <i>COPA</i> gene

ACPA: anti-cyclic citrullinated peptide antibody, AZA: azathioprine, ICS: inhaled corticosteroid, CAM: clarithromycin, NGS: next-generation sequencing

Table S4: Clinical phenotypes of patients with chronic active Epstein-Barr virus disease (CAEBV) and hypersensitivity to mosquito bites (HMB).

Patient	Gender	Age at IS analysis	Disease-onset age	IS	diagnosis	Clinical manifestation at sampling				EBV DNA load in whole blood (copy/ $\mu$ gDNA)	Infected cell type	Treatment
						fever	Skin rash	lymphadenopathy	hepatosplenomegaly			
1	F	1y4m	1y1m	12.2	CAEBV	+	+	+	+	2400	T cell	PSL
2-1		3y4m		3.3		-	+	-	-	32000		None
2-2	F	3y10m	2y4m	13.6	HMB	-	++	-	-	52000	NK cell	None
2-3		5y2m		26.0		-	++	-	-	15000		None

Table S5 : A summary of histological and immunohistochemical findings for the 10 samples studied.

Patient	1	2	3-1	3-2	4	5	6	7	8	9	10
<b>CD163</b>	++	++	N/D	+++	+++	+++	+++	++	++	++	+++
<b>MPO</b>	+++	++	++	+++	+	++	++	+	-	+	++
<b>CD15</b>	+	-	N/D	+++	+	+	-	+	-	+	+
<b>CD123</b>	+	-	N/D	-	-	-	++	-	-	++	+
<b>CD3</b>	+	++	N/D	++	+	++	++	+	++	+++	++
<b>CD20</b>	-	+	N/D	+	+	+	+	-	-	+	+
<b>Derma l infiltrate pattern</b>	Perivas cular and intersti tial	Perivas cular and intersti tial	Perivas cular	Perivas cular	Perivas cular and intersti tial	Perivas cular	Perivas cular and intersti tial	Perivas cular	Superfi cial perivas cular	Perivas cular	Perivas cular and intersti tial
<b>Epider mal change</b>	-	-	-	-	-	-	-	Vacuol ar degener ation	Vacuol ar degener ation	-	-
<b>Vasculi tis</b>	-	-	-	+	-	-	-	-	-	-	-
<b>Pannic ulitis</b>	-	-	N/D	Septal	-	-	-	Lobular	-	-	-

N/D: no data




Figure S1- A heatmap of z-scored relative expression of 6 interferon stimulated genes. Columns show z-scored relative expression of each interferon stimulated gene. Rows show a diagnosis of each patient. Results of re-examination are expressed by ordinal numbers.

Z-scored relative gene expression






Figure S2- Results of the *NF-κB* reporter gene activity assay. All experiments were performed in triplicate. Values are expressed as the mean ± standard deviation (SD). Statistical significance of the difference between the WT and variants stimulated with TNF-α was measured by luciferase activity and analyzed using a one-way ANOVA with Dunnett's multiple comparisons test. Calculated p values are indicated; p < 0.05 with \* and p < 0.001 with \*\*. Suppression of the TNF-α induced *NF-κB* activity by the *TNFAIP3* variants was significantly lower than that seen in the WT.

P1





P2






P3-1

P3-2






P4




P5






P6




P7






P8



P9






Figure S3- *H&E stained sections of patients.* With the exception of the sections for patients P3-2, P7, and P8, all sections showed superficial and deep perivascular dermal infiltrates without epidermal changes, containing mononuclear cells, many of which were MPO-positive and CD15-negative. The skin specimen for P3-2 showed leukocytoclastic vasculitis and septal panniculitis, in addition to dermal infiltrates consisting of matured neutrophils, histiocytes, and lymphocytes. The H&E stained section for patient 7 showed lobular panniculitis, and superficial and deep perivascular dermatitis with vacuolar changes. Cellular infiltrates mainly consisted of MPO-positive and CD163-positive mononuclear cells. The H&E stained section for patient 8 showed superficial perivascular dermatitis with vacuolar degeneration of the basal layer, and exhibited CD3-positive T cell, but not CD20-positive B cell infiltration. The scale bar for all sections represents 50 μm.